Increased bone resorption and osteopenia are a part of the lymphoproliferative phenotype of mice with systemic over-expression of interleukin-7 gene driven by MHC class II promoter

Immunology Letters

Volumn 121, Issue 2, 2008, Pages 134-139

  Salopek, Daniela ^a   Grčević, Danka ^b   Katavić, Vedran ^b   Kovačić, Nataša ^b   Lukić, Ivan Krešimir ^c   Marušić, Ana ^b,d  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c Biosistemi   (Croatia)

^d UNIVERSITY OF SPLIT   (Croatia)

Author keywords

Bone phenotype; Interleukin 7; Osteoblasts; Osteoclasts; Transgenic mice

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; INTERLEUKIN 7;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; BONE MASS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; LONG BONE; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; PHENOTYPE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROMOTER REGION; RHEUMATOID ARTHRITIS; TIBIA; TRABECULAR BONE; TRANSGENIC MOUSE; WILD TYPE;

AGE FACTORS; ANIMALS; ANTIGENS, CD45; BONE DISEASES, METABOLIC; BONE MARROW; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; GENES, MHC CLASS II; INTERLEUKIN-7; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OSTEOCLASTS; PROMOTER REGIONS, GENETIC;

EID: 57449106476     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2008.10.002     Document Type: Article

References (24)

1. Palmer M.J., Mahajan V.S., Trajman L.C., Irvine D.J., Lauffenburger D.A., and Chen J. Interleukin-7 receptor signaling network: an integrated systems perspective. Cell Mol Immunol 2 (2008) 79-89
2. Samaridis J., Casorati G., Traunecker A., Iglesias A., Gutierrez J.C., Mueller U., et al. Development of lymphocytes in interleukin 7-transgenic mice. Eur J Immunol 21 (1991) 453-460
3. Fisher A.G., Burdet C., LeMeur M., Haasner D., Gerber P., and Ceredig R. Lymphoproliferative disorders in an IL-7 transgenic mouse line. Leukemia 2 (1993) 66-68
4. Lee S.K., Kalinowski J.F., Jastrzebski S.L., Puddington L., and Lorenzo J.A. Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis. Endocrinology 144 (2003) 3524-3531
5. Miyaura C., Onoe Y., Inada M., Maki K., Ikuta K., Ito M., et al. Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. Proc Natl Acad Sci USA 94 (1997) 9360-9365
6. Weitzmann N., Roggia C., Toraldo L., Wietzmann L., and Pacifici R. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 110 (2002) 1643-1650
7. Lee S.K., Kalinowski J., Jacquin Q., Douglas J.A., Gronowicz G., and Lorenzo J.A. Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J Bone Miner Res 23 (2006) 695-702
8. Lee S.K., and Surh C.D. Role of interleukin-7 in bone and T-cell homeostasis. Immunol Rev 208 (2005) 169-180
9. Mertsching E., Meyer V., Linares J., Lombard-Platet S., and Ceredig R. Interleukin-7, a non-redundant potent cytokine whose over-expression massively perturbs B-lymphopoiesis. Int Rev Immunol 16 (1998) 285-308
10. Romieu-Mourez R., François M., Boivin M.N., Stagg J., and Galipeau J. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J Immunol 179 (2007) 1549-1558
11. Katavic V., Grcevic D., Lee S.K., Kalinowski J., Jastrzebski S., Dougall W., et al. The surface antigen CD45R identifies a population of estrogen-regulated murine marrow cells that contain osteoclast precursors. Bone 32 (2003) 581-590
12. Katavic V., Lukic I.K., Kovacic N., Grcevic D., Lorenzo J.A., and Marusic A. Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. J Immunol 170 (2003) 1540-1547
13. Grcevic D., Lukic I.K., Kovacic N., Ivcevic S., Katavic V., and Marusic A. Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos. Clin Exp Immunol 146 (2006) 146-158
14. Kovacic N., Lukic I.K., Grcevic D., Katavic V., Croucher P., and Marusic A. The Fas/Fas ligand system inhibits differentiation of murine OBLs but has a limited role in OBL and osteoclast apoptosis. J Immunol 178 (2007) 3379-3389
15. Grcevic D., Lee S.K., Marusic A., and Lorenzo J.A. Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1,25-dihydroxyvitamin D3-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis. J Immunol 165 (2000) 4231-4238
16. Faltynek C.R., Wang S., Miller D., Young E., Tiberio L., Kross K., et al. Administration of human recombinant IL-7 to normal and irradiated mice increases the numbers of lymphocytes and some immature cells of the myeloid lineage. J Immunol 149 (1992) 1276-1282
17. Lorenzo J., Horowitz M., and Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev 29 (2008) 403-440
18. Sato T., Watanabe K., Masuhara M., Hada N., and Hakeda Y. Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by OBLs/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro. J Bone Miner Res 25 (2007) 19-27
19. Toraldo G., Roggia C., Quian W.P., Pacifici R., and Weitzmann M.N. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor κB ligand and tumor necrosis factor α from T cells. PNAS 100 (2003) 125-130
20. Sato T., Shibata T., Ikeda K., and Watanabe K. Generation of bone-resorbing osteoclasts from B220+ cells: its role in accelerated osteoclastogenesis due to estrogen deficiency. J Bone Miner Res 16 (2001) 2215-2221
21. Jacquin C., Gran E.D., Lee S.K., Lorenzo A.J., and Aguila H.L. Identification of multiple osteoclast precursor population in murine bone marrow. J Bone Miner Res 21 (2006) 67-77
22. Carsetti R. The development of B cells in the bone marrow is controlled by the balance between cell-autonomous mechanisms and signals from the microenvironment. J Exp Med 191 (2000) 5-8
23. Iwata M., Graf L., Awaya N., and Torok-Storb B. Functional interleukin-7 receptors (IL-7Rs) are expressed by marrow stromal cells: binding of IL-7 increases levels of IL-6 mRNA and secreted protein. Blood 100 (2002) 1318-1325
24. Boyce B.F., Schwarz E.M., and Xing L. Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. Curr Opin Rheumatol 18 (2006) 427-432